IP Library › Granted Patent US 7,943,755
Granted Patent B2
US 7,943,755 · App. 11/577,663 · Granted May 17, 2011

Neuron regeneration

Assignee: Neuregenix Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,943,755
App. No.
11/577,663
Granted
May 17, 2011
Kind
B2
Abstract

The invention provides a gene silencing molecule, which is adapted to down-regulate expression of a gene encoding a peptide involved with the Rho-A inhibitory pathway. The gene silencing molecule is used to promote neuron survival and axon regeneration in the central nervous system (CNS). The invention also provides compositions and methods of using same to improve neural survival and promote axonal growth.

Claims (20)

1. A gene silencing molecule adapted to down-regulate expression of a gene encoding a peptide involved with the Rho-A inhibitory pathway;

wherein the gene silencing molecule is a short interfering nucleic acid (siNA) comprising:

5′-AAGATTATGACCGTCTGAGGC-3′;

(SEQ ID No. 11)

or

5′-AAGGATCTTCGGAATGATGAG-3′.

(SEQ ID No. 12)

2. A gene silencing molecule according to claim 1 , wherein the siNA molecule comprises an siRNA molecule.

3. A gene silencing molecule according to claim 2 , wherein the siNA molecule comprises between approximately 5 bp and 50 bp.

4. A gene silencing molecule according to claim 2 , wherein the siNA molecule comprises less than 50% GC content.

5. A gene silencing molecule according to claim 1 , wherein the gene silencing molecule comprises a sequence identified as SEQ ID No.12.

6. A gene silencing molecule according to claim 1 , wherein the gene silencing molecule is used in combination with a molecule, which simulates growth of neurites.

7. A gene silencing molecule according to claim 6 , wherein the molecule, which simulates growth of neurites, comprises a neurotrophic factor (NTF).

8. A gene silencing molecule according to claim 7 , wherein the NTF is independently selected from a group consisting of CNTF, FGF2, NGF, NT-3, NT-4, BDNF, GDNF, FGF-1, FGF-5, CT-1, CDF, insulin, IGF-1, IGF-2, IL-6, LIF, NPF, PDGF, PN-1, S-100, TGF-β, and VIP, and the like.

9. A gene silencing molecule according to claim 8 , wherein the NTF is Ciliary Neurotrophic Factor (CNTF) or Fibroblast Growth Factor 2 (FGF2).

10. A medicament comprising a gene silencing molecule according to claim 1 .

11. A gene silencing molecule according to claim 1 , wherein the molecule is adapted to induce more neuron survival and axon growth in the presence of a neurite growth inhibitor molecule than in the absence of the inhibitor molecule.

12. A composition comprising a therapeutically effective amount of a gene silencing molecule according to claim 1 , and a pharmaceutically acceptable vehicle.

13. A composition for promoting neuron survival and axon growth, the composition comprising a gene silencing molecule according to claim 1 , and a neurotrophic growth factor.

14. A composition according to claim 13 , wherein the NTF is independently selected from a group consisting of CNTF, FGF2, NGF, NT-3, NT-4, BDNF, GDNF, FGF-1, FGF-5, CT-1, CDF, insulin, IGF-1, IGF-2, IL-6, LIF, NPF, PDGF, PN-1, S-100, TGF-β, and VIP.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2007
From: AHMED, ZUBAIR; BERRY, MARTIN; LOGAN, ANN
To: NEUREGENIX LIMITED
Reel/Frame 019570/0884 →
Continuity (1)
Related Publication 20080253989A1 · Oct 16, 2008